420 related articles for article (PubMed ID: 26459251)
1. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.
Jia J; Cui Y; Lu M; Wang X; Li J; Li J; Li Y; Zhang X; Gao J; Zhou J; Lu Z; Gong J; Yu J; Sun Z; Liu C; Shen L; Zhang X
Clin Transl Oncol; 2016 Jun; 18(6):592-8. PubMed ID: 26459251
[TBL] [Abstract][Full Text] [Related]
2. Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: A single centre prospective phase II trial.
Lu M; Wang X; Shen L; Jia J; Gong J; Li J; Li J; Li Y; Zhang X; Lu Z; Zhou J; Zhang X
Cancer Sci; 2016 Apr; 107(4):486-90. PubMed ID: 26797530
[TBL] [Abstract][Full Text] [Related]
3. A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.
Wang HY; Yao ZH; Tang H; Zhao Y; Jin SL; Zhou WP; Yao SN; Yang SJ; Liu YY; Luo SX
Oncotarget; 2017 Jan; 8(5):7540-7547. PubMed ID: 27902478
[TBL] [Abstract][Full Text] [Related]
4. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy.
Huang J; Zhou Y; Zhang H; Qu T; Mao Y; Zhu H; Quan L; Xing P; Wang J; He J; Xu N; Sun Y
Med Oncol; 2013 Mar; 30(1):343. PubMed ID: 23263828
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor is a prognosis predictor in patients with esophageal squamous cell carcinoma.
Zhang W; Zhu H; Liu X; Wang Q; Zhang X; He J; Sun K; Liu X; Zhou Z; Xu N; Xiao Z
Ann Thorac Surg; 2014 Aug; 98(2):513-9. PubMed ID: 24881860
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
8. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Chen Y; Wu X; Bu S; He C; Wang W; Liu J; Guo W; Tan B; Wang Y; Wang J
Cancer Sci; 2012 Nov; 103(11):1979-84. PubMed ID: 22845557
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.
Kim HS; Kim SM; Kim H; Pyo KH; Sun JM; Ahn MJ; Park K; Keam B; Kwon NJ; Yun HJ; Kim HG; Chung IJ; Lee JS; Lee KH; Kim DJ; Lee CG; Hur J; Chung H; Park JC; Shin SK; Lee SK; Kim HR; Moon YW; Lee YC; Kim JH; Paik S; Cho BC
Oncotarget; 2015 Dec; 6(42):44971-84. PubMed ID: 26462025
[TBL] [Abstract][Full Text] [Related]
10. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study.
Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W
J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263
[TBL] [Abstract][Full Text] [Related]
11. High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis.
Wang CY; Deng JY; Cai XW; Fu XL; Li Y; Zhou XY; Wu XH; Hu XC; Fan M; Xiang JQ; Zhang YW; Chen HQ; Perez R; Jiang GL; Zhao KL
Oncotarget; 2015 Jul; 6(21):18674-82. PubMed ID: 26124180
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
13. Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma.
Si X; Wu S; Wang H; Zhang X; Wang M; Zeng X; Zhang L
Thorac Cancer; 2018 Aug; 9(8):1056-1061. PubMed ID: 29920955
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World.
Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A
Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma.
Zhao C; Lin L; Liu J; Liu R; Chen Y; Ge F; Jia R; Jin Y; Wang Y; Xu J
Oncotarget; 2016 Aug; 7(35):57310-57316. PubMed ID: 28087951
[TBL] [Abstract][Full Text] [Related]
16. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3.
Zhao L; He LR; Xi M; Cai MY; Shen JX; Li QQ; Liao YJ; Qian D; Feng ZZ; Zeng YX; Xie D; Liu MZ
J Transl Med; 2012 Dec; 10():249. PubMed ID: 23232108
[TBL] [Abstract][Full Text] [Related]
17. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study.
Lee SJ; Kim S; Kim M; Lee J; Park YH; Im YH; Park SH
BMC Cancer; 2015 Oct; 15():693. PubMed ID: 26468007
[TBL] [Abstract][Full Text] [Related]
18. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin.
Zhao L; Li QQ; Zhang R; Xi M; Liao YJ; Qian D; He LR; Zeng YX; Xie D; Liu MZ
Tumour Biol; 2012 Aug; 33(4):1115-23. PubMed ID: 22389159
[TBL] [Abstract][Full Text] [Related]
19. Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma.
Xu Y; Peng Z; Li Z; Lu M; Gao J; Li Y; Li Y; Shen L
BMC Cancer; 2015 Jan; 15():6. PubMed ID: 25588551
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of EGFR family expression in lymph node-negative esophageal squamous cell carcinoma patients.
Yu W; Yang X; Chu L; Zhao K; Chen H; Xiang J; Zhang Y; Li H; Zhao W; Sun M; Wei Q; Fu X; Xie C; Zhu Z
Pathol Res Pract; 2018 Jul; 214(7):1017-1023. PubMed ID: 29729836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
